Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P22059

UPID:
OSBP1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P22059; Q6P524

BACKGROUND:
The Oxysterol-binding protein 1 (OSBP1) is integral to the countertransport of lipids between the Golgi apparatus and the endoplasmic reticulum, facilitating the exchange of sterol with phosphatidylinositol 4-phosphate. It binds to cholesterol and oxysterols, influencing cellular signaling pathways, including the dephosphorylation of ERK1/2 and the stability of ABCA1, a key protein in cholesterol efflux. These functions underscore OSBP1's critical role in lipid metabolism and cellular signaling.

THERAPEUTIC SIGNIFICANCE:
The exploration of Oxysterol-binding protein 1's functions offers a promising avenue for the development of novel therapeutic approaches. Given its central role in lipid metabolism and signaling pathways, targeting OSBP1 could provide innovative treatments for metabolic disorders and diseases linked to cholesterol dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.